Ascopiave Valuation
Is 0DME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0DME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0DME (€2.32) is trading above our estimate of fair value (€2.19)
Significantly Below Fair Value: 0DME is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0DME?
Other financial metrics that can be useful for relative valuation.
| What is 0DME's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €524.44m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.1x |
| Enterprise Value/EBITDA | 9.3x |
| PEG Ratio | -85.5x |
Price to Earnings Ratio vs Peers
How does 0DME's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.6x | ||
JEL Jersey Electricity | 12.5x | -8.5% | UK£140.9m |
YU. Yü Group | 10.2x | 7.9% | UK£313.5m |
1600 Tian Lun Gas Holdings | 9.1x | 13.1% | HK$4.7b |
8908 ShinHsiung Natural Gas | 30.4x | n/a | NT$15.8b |
0DME Ascopiave | 14.5x | -0.2% | €524.4m |
Price-To-Earnings vs Peers: 0DME is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (15.6x).
Price to Earnings Ratio vs Industry
How does 0DME's PE Ratio compare vs other companies in the Global Gas Utilities Industry?
Price-To-Earnings vs Industry: 0DME is expensive based on its Price-To-Earnings Ratio (14.5x) compared to the Global Gas Utilities industry average (14x).
Price to Earnings Ratio vs Fair Ratio
What is 0DME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0DME's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €3.05 0% | 4.9% | €3.20 | €2.90 | n/a | 2 |
| Apr ’25 | €2.37 | €3.05 +29.0% | 4.9% | €3.20 | €2.90 | n/a | 2 |
| Mar ’25 | €2.30 | €3.30 +43.5% | 3.0% | €3.40 | €3.20 | n/a | 2 |
| Feb ’25 | n/a | €3.30 0% | 3.0% | €3.40 | €3.20 | n/a | 2 |
| Jan ’25 | n/a | €3.30 0% | 3.0% | €3.40 | €3.20 | n/a | 2 |
| Dec ’24 | €2.25 | €3.30 +46.7% | 3.0% | €3.40 | €3.20 | n/a | 2 |
| Nov ’24 | €2.09 | €3.50 +67.5% | 2.9% | €3.60 | €3.40 | n/a | 2 |
| Oct ’24 | €1.99 | €3.50 +75.9% | 2.9% | €3.60 | €3.40 | n/a | 2 |
| Sep ’24 | €2.16 | €3.50 +62.4% | 2.9% | €3.60 | €3.40 | n/a | 2 |
| May ’24 | n/a | €4.05 0% | 11.1% | €4.50 | €3.60 | n/a | 2 |
| Apr ’24 | €2.67 | €4.05 +51.7% | 11.1% | €4.50 | €3.60 | €2.37 | 2 |
| Mar ’24 | €2.70 | €4.05 +50.0% | 11.1% | €4.50 | €3.60 | €2.30 | 2 |
| Feb ’24 | €2.65 | €4.10 +54.7% | 9.8% | €4.50 | €3.70 | n/a | 2 |
| Jan ’24 | €2.41 | €4.10 +70.1% | 9.8% | €4.50 | €3.70 | n/a | 2 |
| Dec ’23 | €2.53 | €4.10 +62.4% | 9.8% | €4.50 | €3.70 | €2.25 | 2 |
| Nov ’23 | €2.37 | €4.10 +73.4% | 9.8% | €4.50 | €3.70 | €2.09 | 2 |
| Oct ’23 | €2.21 | €4.10 +85.5% | 9.8% | €4.50 | €3.70 | €1.99 | 2 |
| Sep ’23 | €2.47 | €4.10 +66.3% | 9.8% | €4.50 | €3.70 | €2.16 | 2 |
| Aug ’23 | €2.79 | €4.35 +55.9% | 3.4% | €4.50 | €4.20 | n/a | 2 |
| Jul ’23 | €2.93 | €4.35 +48.7% | 3.4% | €4.50 | €4.20 | €2.37 | 2 |
| Jun ’23 | €3.32 | €4.35 +31.2% | 3.4% | €4.50 | €4.20 | n/a | 2 |
| May ’23 | €3.53 | €4.35 +23.2% | 3.4% | €4.50 | €4.20 | n/a | 2 |
| Apr ’23 | €3.52 | €4.35 +23.8% | 3.4% | €4.50 | €4.20 | €2.67 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.